Cinolazepam

Cinolazepam[2] (marketed under the brand name Gerodorm)[3] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.

Cinolazepam
Clinical data
Trade namesGerodorm
AHFS/Drugs.comcinolazepam
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • US: Schedule IV
Pharmacokinetic data
Bioavailability90–100%
MetabolismHepatic
Elimination half-life3.8 hours[1]
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC18H13ClFN3O2
Molar mass357.8 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
 NY (what is this?)  (verify)

It was patented in 1978 and came into medical use in 1992.[4] Cinolazepam is not approved for sale in the United States or Canada.

References

  1. "ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS" (Press release). (in Austrian German). Austria: G.L. Pharma GmbH. Bundesamt für Sicherheit im Gesundheitswesen. October 2018. Archived from the original on 2019-01-02. Retrieved 2019-01-02.
  2. US Patent 4388313 Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof
  3. Lannacher Romania (1999). "Gerodorm". Produse Gerot inregistrate in Romania (in Romanian). Archived from the original on 11 October 2006. Retrieved 17 August 2006.
  4. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 530. ISBN 9783527607495.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.